Serina Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,672 | $7,619 |
| Prepaid expenses and other current assets | 2,004 | — |
| Total current assets | 5,676 | 7,619 |
| Property and equipment, net | 501 | 573 |
| Right of use assets - operating leases | 461 | 666 |
| Right of use assets - finance leases | 86 | 110 |
| TOTAL ASSETS | $6,724 | $8,968 |
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY/(DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $744 | $580 |
| Accrued expenses | 1,429 | 583 |
| Other current liabilities | 193 | 250 |
| Total current liabilities | 2,366 | 1,413 |
| Warrant liability | 3,582 | — |
| Convertible promissory notes, at fair value | — | 2,983 |
| Operating lease liabilities, net of current portion | 268 | 461 |
| Finance lease liabilities, net of current portion | — | 1 |
| TOTAL LIABILITIES | 6,216 | 4,858 |
| Commitments and contingencies (Note 12) | ||
| Redeemable convertible preferred stock: | ||
| Redeemable convertible preferred stock, $0.01 par value; 10,000 shares authorized; zero and 3,438 shares issued and outstanding at December 31, 2024 and 2023, respectively; Liquidation preference of zero and $36,982 at December 31, 2024 and 2023, respectively | — | 36,404 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.0001 par value, 40,000 shares authorized; and 9,422 and 2,410 shares issued and outstanding at December 31, 2024 and 2023, respectively | 1 | — |
| Additional paid-in capital | 44,958 | 883 |
| Accumulated deficit | (44,318) | (33,177) |
| Total Serina Therapeutics, Inc. stockholders’ equity (deficit) | 641 | (32,294) |
| Noncontrolling interest | (133) | — |
| Total stockholders’ equity (deficit) | 508 | (32,294) |
| TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY(DEFICIT) | $6,724 | $8,968 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.